COVID-19 Global Updates & Resources

This Phase 2 trial is underway to determine the safety, efficacy, tolerability and Pharmacokinetics of ARGX-113 in patients with primary immune thrombocytopenia. The primary focus of this study is to determine if this treatment lowers incidence and severity of serious adverse events. ARGX-113, Efgartigimod, works by degrading circulating disease-causing autoimmune antibodies.

United Kingdom, Austria, Belgium, France, Germany, Hungary, Poland, Spain, Ukraine, Czechia